Marc Beer Renovia

Posted by

Entrepreneurship requires vision to see an opportunity everywhere which solves a problem and to have great resourcefulness (Businessnewdaily.com). Marc Beer exemplifies these attributes of what an entrepreneur should possess. Marc Beer was able to raise $42 million for Renovia, a biotechnology company (he co-founded) that produces products to treat pelvic floor disorders such as urinary incontinence (Bizjournal.com). Pelvic floor disorders affect 250 million women worldwide. The product, Leva, received FDA approval in April 2018 (Bizjournal.com). Healthcare-focused firm, Longwood, Perceptive Advisors and Ascension Ventures invested in Renovia that helped in developing Leva. Because of the investment, Renovia can develop and test for more therapeutic products including a newer version of the Leva device (Businessnewsdaily.com).

 

 

 

Marc Beer has more than 25 years of experience in developing and commercializing areas of the biotechnology industry (Renoviainc.com). He worked in sales and marketing in pharmaceutical and diagnostic divisions of Abbot Laboratories. Marc He held various roles with Genzyme, a biotech company that research treatments for debilitating diseases, such as multiple sclerosis (SanofiGenzyme.com). He was responsible for the commercial launch of several products that addressing rare diseases worldwide (Renoviainc.com). In 2000, Marc was Founding CEO of ViaCell, a biotechnology company that specialized in the development, collection and preservation of umbilical cord blood stem cells (Renoviainc.com). He served as a member of the board of directors of Erytech Pharma. Marc was a member of the Mass Life Science Board of the Commonwealth of Massachusetts and served on board of Biotechnology Industry Organization Emerging Companies Section Governing Board. He serves as chairman of the board of directors at Good Start Genetics and Minerva Neurosciences (Bizjournal.com). Minerva Neurosciences is a company that research and develops products that address diseases such as Parkinson’s disease, or Major Depressive Disorders (Minervaneurosciences.com). Marc also is a strategic consultant to OvaScience. OvaScience is a company that addresses couples inability to have children (OvaScience.com). Marc Beer is experienced in helping develop biotech companies that have made contributions addressing the issues of people who are burden with rare diseases or ailments. Because he has experience in the biotechnology field, he can use his influence to other investors to take an initiative in supporting startup companies in this field. Learn more: https://www.benzinga.com/pressreleases/18/08/r12237847/osf-ventures-invests-in-company-developing-solutions-for-pelvic-floor-